Project Details
Description
ABSTRACT – BIOSPECIMENS AND PATIENT REGISTRY CORE (CORE B)
The goal of the Biospecimens and Patient Registry Core (Core B) is to provide the Mayo Clinic SPORE in
Ovarian Cancer investigators with high quality patient clinical data, DNA, RNA, blood products, and tissues
(normal and malignant) from consented patients with ovarian, fallopian tube, or primary peritoneal carcinoma
and suitable controls, and to make these resources available for future studies. The Mayo Clinic has a strong
tradition of ethically sound support of research that links tissue acquisition and patient data records. Paraffin
embedded tissues, histological slides, and associated patient charts from surgeries performed since the first
decade of the 1900's are maintained in Mayo’s Tissue Registry and the Mayo Archives. Core B interacts with
i) the Pathology Research Core of the Mayo Clinic Cancer Center, which provides expertise, collaborative
support, and service for immunohistochemistry, in situ hybridization, tissue microarray construction, and digital
imaging; ii) the Biospecimens Accessioning and Processing Core, which is the primary site of accessioning
and standardized processing of blood and frozen tissue collected explicitly for research from all three Mayo
sites; and iii) the Cytogenetics Core, which has expertise in establishing, validating, and scoring fluorescence
in situ hybridization (FISH) studies. Core B is integrated with these existing tissue-oriented Cancer Center
shared resources and other scientific Cores of this SPORE to provide a coordinated, centralized, dedicated
program for standardized collection, accessioning, processing, morphologic classification, and genomic
annotation of biospecimens so that these can be studied in the context of patient data from fully consented
patients. Thorough clinical annotation is required to maximize the potential use of tissue specimens in
translational research; therefore, risk factor questionnaires, clinical records, and pathology review are
incorporated into the Core. Research services, including pathologic review of tumor histology, tumor sectioning
and quality control, blood processing, construction of tissue microarrays (TMAs), immunohistochemistry (IHC),
and FISH, will be provided as needed to SPORE investigators. Core B is closely coordinated with the
Biostatistics and Bioinformatics Core (Core C) to provide seamless linkage of clinical annotation with research
specimens for data management and analyses. In Years 6-10 of Mayo Clinic SPORE in Ovarian Cancer
funding, Core B distributed 4326 ovarian tumor tissues, 511 TMA slides, and 3628 germline DNA samples. In
addition, Core B undertook a systematic evaluation of common ovarian cancer susceptibility genes in all stored
cancer specimens and successfully collaborated with a stem cell biologist, new to ovarian cancer research, to
generate a novel biospecimen—benign Fallopian tube organoids from women at average risk and high risk
(BRCA1/2, RAD51C, and other carriers) of ovarian cancer. Under the direction of the Administrative Core, the
Biospecimens and Patient Registry Core will continue to make biospecimens collected for this SPORE
available to SPORE investigators and the ovarian cancer research community at large in order to stimulate
translational research with the goal of reducing the burden of ovarian cancer.
Status | Active |
---|---|
Effective start/end date | 9/1/21 → 8/31/24 |
Funding
- National Cancer Institute: $185,762.00
- National Cancer Institute: $190,434.00
- National Cancer Institute: $185,323.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.